Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Henry Jacob Conter"'
Publikováno v:
BMC Medical Education, Vol 20, Iss 1, Pp 1-9 (2020)
BMC Medical Education
BMC Medical Education
Background Direct observation is necessary for specific and actionable feedback, however clinicians often struggle to integrate observation into their practice. Remotely audio-monitoring trainees for periods of time may improve the quality of written
Autor:
Ravnoor Kang, Rachel Dhir, Marco Iafolla, William Raskin, Shaan Dudani, Juhi Husain, Margaret Balcewicz, Philip G. Kuruvilla, Stephen Reingold, Henry Jacob Conter, Shyam Ravisankar, Rardi Van Heest, Parneet Kaur Cheema, Kirstin Perdrizet
Publikováno v:
Journal of Clinical Oncology. 40:e18631-e18631
e18631 Background: Cancer patients have a high risk of severe illness from COVID-19 infection, and the William Osler Health System oncology clinic (WOHS-OC) is in Brampton, ON, Canada, a COVID-19 hotspot with high community COVID-19 prevalence. As su
Autor:
Michael McCleod, Alona Zer, Steven L. McCune, Marcin Kowanetz, Henry Jacob Conter, Hans-Georg Kopp, Tarek Mekhail, Niels Reinmuth, W. Lin, Ahad Sadiq, Lijia Wang, Alan Sandler, Maen A. Hussein, Federico Cappuzzo, V. Archer, Achim Rittmeyer, Davey B. Daniel, Howard Jack West, Tania Ochi Lohmann, Alessandro Morabito
Publikováno v:
The Lancet Oncology. 20:924-937
Summary Background Atezolizumab (a monoclonal antibody against PD-L1), which restores anticancer immunity, improved overall survival in patients with previously treated non-small-cell lung cancer and also showed clinical benefit when combined with ch
Autor:
Dean Fergusson, Lisa Vandermeer, Greg Pond, William Raskin, Carol Stober, Mihaela Mates, Brian Hutton, Sukhbinder Dhesy-Thind, Henry Jacob Conter, Arif Awan, Demetrios Simos, REaCT investigators, Deanna Saunders, Mark Clemons, Vikaash Kumar, Terry L. Ng
Publikováno v:
Journal of Bone Oncology, Vol 26, Iss, Pp 100343-(2021)
Journal of Bone Oncology
Journal of Bone Oncology
Highlights • Adjuvant bisphosphonates are an established standard in postmenopausal breast cancer. • Guidelines note the need to explore different agents, doses, and intervals of bisphosphonates. • Feasibility of randomizing to 6-monthly vs one
Autor:
Cristiano Ferrario, Josep M. Piulats, Mark David Linch, Michael Stoeckle, Brigitte Laguerre, José A. Arranz, Tilman Todenhöfer, Peter C.C. Fong, William R. Berry, Urban Emmenegger, Loic Mourey, Nataliya Mar, Leonard Joseph Appleman, Anthony M. Joshua, Henry Jacob Conter, Xin Tong Li, Charles Schloss, Christian Heinrich Poehlein, Johann S. De Bono, Evan Y. Yu
Publikováno v:
Journal of Clinical Oncology. 40:118-118
118 Background: Abi + p is a standard of care for mCRPC. Cohort D of the phase 1b/2 KEYNOTE-365 study (NCT02861573) was used to evaluate safety and efficacy of the PD-1 inhibitor pembro + abi and p in patients (pts) who had not received chemotherapy
Autor:
Anthony M. Joshua, Evan Y. Yu, Loic Mourey, Srikala S. Sridhar, William R. Berry, Heshui Wu, Josep M. Piulats, Christian Heinrich Poehlein, Urban Emmenegger, Howard Gurney, Charles Schloss, J. De Bono, Henry Jacob Conter, Michael Paul Kolinsky, Emanuela Romano, G. Gravis, Margitta Retz, Leonard Joseph Appleman, B. Laguerre, Martin Boegemann
Publikováno v:
European Urology Open Science, Vol 19, Iss, Pp e871-e872 (2020)
Autor:
B. Laguerre, Charles Schloss, Urban Emmenegger, Josep M. Piulats, Howard Gurney, Loic Mourey, Christian Heinrich Poehlein, Evan Y. Yu, Peter C.C. Fong, Heshui Wu, Susan Feyerabend, Audrey E. Kam, N.D. Shore, Margitta Retz, Leonard Joseph Appleman, Emanuela Romano, Henry Jacob Conter, J. De Bono, G. Gravis, William R. Berry
Publikováno v:
European Urology Open Science, Vol 19, Iss, Pp e875-e876 (2020)
Autor:
Gwenaelle Gravis, Loic Mourey, Neal D. Shore, Helen Wu, Christian Heinrich Poehlein, Josep M. Piulats, Howard Gurney, William R. Berry, Evan Y. Yu, Emanuela Romano, Brigitte Laguerre, Margitta Retz, Susan Feyerabend, Leonard Joseph Appleman, Henry Jacob Conter, Johann S. de Bono, Audrey E. Kam, Urban Emmenegger, Peter Fong
Publikováno v:
Journal of Urology. 203
INTRODUCTION AND OBJECTIVE:The mechanisms of action of enzalutamide (enza) and pembrolizumab (pembro) may be synergistic in metastatic castration-resistant prostate cancer (mCRPC) and previous work...
Autor:
Christina Canil, Christian Kollmannsberger, Lori Wood, Jeffrey Graham, M. Neil Reaume, Phillippe Violette, Scott North, Francois Patenaude, Ranjena Maloni, Daniel Y.C. Heng, Pierre I. Karakiewicz, Sebastien J. Hotte, Piotr Czaykowski, Samantha Gray, Georg A. Bjarnason, Naveen S. Basappa, Shaan Dudani, Henry Jacob Conter, Anil Kapoor, Aly-Khan A. Lalani, Denis Soulières, Eric Winquist
Publikováno v:
Canadian Urological Association journal = Journal de l'Association des urologues du Canada. 13(10)
Advanced RCC has seen many treatment advances in the last several years, with the introduction of many novel therapies. Recent evidence from the KEYNOTE 426 and CheckMate 214 studies has mandated a rearrangement of treatment algorithms for advanced c
Autor:
Leonard Joseph Appleman, Emanuela Romano, Henry Jacob Conter, Evan Y. Yu, Johann S. de Bono, Loic Mourey, Charles Schloss, Gwenaelle Gravis, Urban Emmenegger, Howard Gurney, Josep M. Piulats, Neal D. Shore, Margitta Retz, Xin Tong Li, Tilman Todenhoefer, Christian Heinrich Poehlein, Cristiano Ferrario, Brigitte Laguerre, William R. Berry, Peter C.C. Fong
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundPrevious data from cohort C of phase 1b/2 study KEYNOTE-365 (NCT02861573) showed that PD-1 inhibitor pembrolizumab + enzalutamide was well tolerated and showed antitumor activity in patients with abiraterone acetate–pretreated mCRPC. Upda